Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1791 results
September 2023
-
Ad-hoc Release
Sandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statements
Ad hoc announcement pursuant to Art. 53 LRSupplement published by Sandoz ahead of Novartis Extraordinary General Meeting on September 15, 2023H1 results demonstrated continued momentum with strong… -
Ad-hoc Release
Sandoz publie un supplément au prospectus de cotation comprenant les états financiers de Sandoz au premier semestre 2023
Annonce ad hoc en vertu de l’art. 53 LRSupplément publié par Sandoz avant l’Assemblée générale extraordinaire de Novartis du 15 septembre 2023Les résultats du premier semestre ont… -
Ad-hoc Release
Sandoz veröffentlicht Nachtrag zum Kotierungsprospekt, einschliesslich Finanzabschluss von Sandoz für das 1. Halbjahr 2023
Ad-hoc-Mitteilung gemäss Art. 53 LRNachtrag von Sandoz veröffentlicht vor der ausserordentlichen Generalversammlung von Novartis am 15. September 2023Die Ergebnisse des ersten… -
Statement
Novartis statement on filing of Inflation Reduction Act lawsuit
August 2023
-
Statement
Novartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program
-
Press Release
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six… -
Press Release
Sandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolio
Sandoz completes acquisition of worldwide brand rights for Mycamine® (micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly… -
Press Release
Sandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
Biosimilar Tyruko® approved for all indications of reference medicine, with same dosing and administration schedule Sandoz continues to expand access to much-needed medications for patients… -
Ad-hoc Release
Novartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off vote
Ad hoc announcement pursuant to Art. 53 LR Invitation to Novartis Extraordinary General Meeting on September 15, 2023, and Shareholder Information Brochure issuedSandoz Listing Prospectus… -
Ad-hoc Release
Novartis publiziert Einladung und Aktionärsbroschüre zur ausserordentlichen Generalversammlung. Sandoz veröffentlicht den Kotierungsprospekt im Vorfeld der Abstimmung zum vorgeschlagenen Spin-off
Ad-hoc-Meldung nach Art. 53 LR Einladung zur ausserordentlichen Generalversammlung von Novartis am 15. September 2023 und Informationsbroschüre für Aktionärinnen und Aktionäre publiziertSandoz… -
Ad-hoc Release
Novartis publie l’invitation à l’AGE et la brochure d’information aux actionnaires. Sandoz publie le prospectus de cotation avant le vote sur la proposition de scission
Annonce ad hoc en vertu de l’art. 53 LR Invitation à l’assemblée générale extraordinaire de Novartis du 15 septembre 2023 et publication d’une brochure d’information destinée… -
Press Release
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept
Mylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new affordable option for patients with nAMD, a leading…